Hyloris Pharmaceuticals, Wake Forest University to Develop Rare Skin Disorder Therapy

12:05 AM EST, 12/12/2025 (MT Newswires) -- Hyloris Pharmaceuticals (HYL.BR) signed an exclusive license option agreement with US-based research institution Wake Forest University School of Medicine to develop a new topical therapy for a rare inherited skin disorder. Under the research collaboration, Wake Forest University School of Medicine will assess the safety and initial efficacy of the investigational topical therapy in an exploratory clinical trial, according to a Thursday release. Upon completion of the trial, the biopharma company will hold an exclusive option to obtain a license and global commercial rights to the therapy. The companies are also seeking patent protection in several key jurisdictions.